A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy – The PROPER 1 trial

A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy – The PROPER 1 trial

Background and purpose: The treatment of biochemical recurrence (BCR) after prostatectomy is challenging as the site of the recurrence is often undetectable. Our aim was to test a personalised treatment concept for BCR based on PSA kinetics during salvage radiotherapy (SRT) combined with prostate-sp...

Full description

Bibliographic Details
Main Authors:	Adalsteinn Gunnlaugsson, Vilberg Johannesson, Elinore Wieslander, Eva Brun, Ulrika Bitzén, Olof Ståhl, Ola Bratt, Göran Ahlgren, Tomas Ohlsson, Elisabeth Kjellén, Per Nilsson
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Series:	Clinical and Translational Radiation Oncology
Subjects:	Salvage radiotherapy Prostate cancer Adaptive Prostate specific antigen Prostate specific membrane antigen
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405630822000544

Similar Items

Salvage conformal radiotherapy for biochemical recurrent prostate cancer after radical prostatectomy
by: Carlos R. Monti, et al.
Published: (2006-08-01)

Adaptive sequential plan-on-plan optimization during prostate-specific antigen response guided radiotherapy of recurrent prostate cancer
by: Vilberg Jóhannesson, et al.
Published: (2021-04-01)

Dose-volume relationships of planned versus estimated delivered radiation doses to pelvic organs at risk and side effects in patients treated with salvage radiotherapy for recurrent prostate cancer
by: Vilberg Jóhannesson, et al.
Published: (2024-03-01)

Predictive factors for disease progression after salvage radiation therapy in biochemical recurrent patients treated by radical prostatectomy
by: Koichi Aikawa, et al.
Published: (2023-09-01)

Long-term Outcomes and Patient Satisfaction Following Salvage Robot-assisted Radical Prostatectomy: A Modern Perspective
by: Daniel J. Lama, et al.
Published: (2024-02-01)

PSA decay during salvage radiotherapy for prostate cancer as a predictor of disease outcome – 5 year follow-up of a prospective observational study
by: Adalsteinn Gunnlaugsson, et al.
Published: (2020-09-01)

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review
by: Arslaan Javaeed, et al.
Published: (2020-05-01)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
by: Daniel Simanjuntak, et al.
Published: (2016-03-01)

Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience
by: Jure Murgic, et al.
Published: (2021-05-01)

Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
by: Xing Zhou, et al.
Published: (2022-01-01)

Anti-Tumor Efficacy of Gene Vaccine Expressing PSMA
by: Yue-hong ZHANG, et al.
Published: (2010-12-01)

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer
by: Ahmad Anies Shahab, et al.
Published: (2013-03-01)

Body mass index in relation to prostate-specific antigen-related parameters
by: Dandan Lin, et al.
Published: (2021-09-01)

Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer
by: Sinan Avci, et al.
Published: (2020-04-01)

Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and Its Role in Salvage Lymph Node Dissection
by: Marieke J. Krimphove, et al.
Published: (2020-01-01)

DIAGNOSIS OF PROSTATIC NEOPLASM LATER TO ANTIBIOTIC TREATMENT IN PATIENTS WITH PROSTATE-SPECIFIC ANTIGEN BETWEEN 4 AND 10 ng/ml (IN SPANISH)
by: Infantes-Burgos Ronald Javier, et al.
Published: (2014-01-01)

Moving ahead of prostate-specific antigen
by: Banyameen Mohamad Iqbal, et al.
Published: (2016-01-01)

Elevated prostate volume index and prostatic chronic inflammation reduce the number of positive cores at first prostate biopsy set: results in 945 consecutive patients
by: Antonio B. Porcaro, et al.

Biochemical recurrence after radical prostatectomy: what does it mean?
by: Rafael Tourinho-Barbosa, et al.

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia
by: Yasuhide Kitagawa, et al.
Published: (2015-06-01)

The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy
by: Heikki Seikkula, et al.
Published: (2024-11-01)

Effect of Temperature and Humidity on Serum Prostate Specific Antigen Levels in Asymptomatic Male Population
by: Murat Tuğrul Eren, et al.
Published: (2016-12-01)

Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels
by: Sillerud LO
Published: (2016-01-01)

Research Progress of PSMA-Targeted Small Molecule Drugs
by: MU Boshuai;XU Yang;LIU Zhibo
Published: (2021-12-01)

The Efficiency of the Serum Prostate Specific Antigen Levels in Diagnosing Prostatic Enlargements
by: Ingle SP, et al.
Published: (2013-01-01)

Impact of lymphovascular invasion on lymph node metastasis for patients undergoing radical prostatectomy with negative resection margin
by: Yong Jin Kang, et al.
Published: (2017-05-01)

Epidemiological Study of Patients with Prostate Cancer in South of Iraq
by: Manal Badi Salih Al-Tmemi
Published: (2019-07-01)

Review of Clinical Manifestations of Biochemically-advanced Prostate Cancer Cases
by: Edmund Chiong, et al.
Published: (2005-07-01)

Metastatic prostate cancer in the modern era of PSA screening
by: Philip A. Fontenot Jr, et al.

Possible association between periodontitis and prostatitis: A pilot study
by: Stefanovska Emilija S., et al.
Published: (2021-01-01)

Prostate Specific Antigen (PSA): The Historical Perspective
by: T. Ming Chu
Published: (2020-12-01)

Orbital and brain metastases on 68Ga-PSMA PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy
by: Ashwin Singh Parihar, et al.
Published: (2021-01-01)

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
by: Eline A.M. Ruigrok, et al.
Published: (2019-10-01)

CUT-OFF VALUES OF PROSTATE SPECIFIC ANTIGEN DENSITY– AN EFFECTIVE SCREENING MARKER BEFORE PROSTATE BIOPSY
by: Zujaja Hina Haroon, et al.
Published: (2022-03-01)

Research of the best screen interval for middle aged and elderly Chinese males with baseline prostate specific antigen levels <2.0 ng/mL in prostate cancer screening
by: Yu Chen, et al.
Published: (2024-09-01)

The value of 18F-PSMA-1007 PET/CT in preoperative evaluation of prostate cancer within PSA gray area
by: Shuying Bian, et al.
Published: (2024-08-01)

Specificity and sensitivity of preoperative total serum prostate specific antigen in diagnosis most common histopathological change of prostate
by: Mijović Milica, et al.
Published: (2017-01-01)

Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan
by: Yasuhide Kitagawa, et al.
Published: (2014-12-01)

The diagnostic value of a new formula combining age and prostate volume in prostate cancer
by: Xiaobo Yang, et al.
Published: (2022-02-01)

Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer
by: Ho Won Kang, et al.
Published: (2016-01-01)